Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial
Jason Weatherald(University of Alberta), Naushad Hirani(University of Calgary), Chidera Nwaroh(University of Calgary), Lea Harper(University of Calgary), Jonathan Liu(University of Calgary), Doug Helmersen(University of Calgary), L. Kolkman(University of British Columbia), Omid Kiamanesh(University of Calgary), Mithum Kularatne(University of Calgary), Christina S. Thornton(University of Calgary), Rhea Varughese(University of Alberta), Nathan W. Brunner(University of British Columbia), Mitesh V. Thakrar(University of Calgary), Evan Orlikow(University of Manitoba), John R. Swiston(University of British Columbia), Nowell M. Fine(University of Calgary)
Cited by 12
Related Papers
Outcome Prediction by Quantitative Right Ventricular Function Assessment in 575 Subjects Evaluated for Pulmonary Hypertension
|Circulation Cardiovascular Imaging|2013|439
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice
|JACC Heart Failure|2019|345
Pseudomonas aeruginosa in chronic lung disease: untangling the dysregulated host immune response
|Frontiers in Immunology|2024|52
Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values
|Antimicrobial Resistance and Infection Control|2022|47
The respiratory microbiome and nontuberculous mycobacteria: an emerging concern in human health
|European Respiratory Review|2021|45